Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Oct 2;18(12):83.
doi: 10.1007/s11910-018-0894-7.

Longitudinal Progression Markers of Parkinson's Disease: Current View on Structural Imaging

Jing Yang  1 , Roxana G Burciu  2   3 , David E Vaillancourt  4
Affiliations
Review

Longitudinal Progression Markers of Parkinson's Disease: Current View on Structural Imaging

Jing Yang et al. Curr Neurol Neurosci Rep. .

Abstract

Purpose of review: Advances in neuroimaging techniques pave a rich avenue for in vivo progression biomarkers, which can objectively and noninvasively assess the long-term dynamic alterations in the brain of Parkinson's disease (PD) patients. This article reviews recent progress in structural magnetic resonance imaging (MRI) tools to track disease progression in PD, and discusses specific criteria a neuroimaging tool needs to meet to be a progression biomarker of PD and the potential applications of these techniques in PD based on current evidence.

Recent findings: Recent longitudinal studies showed that quantitative structural MRI markers derived from T1-weighted, diffusion-weighted, neuromelanin-sensitive, and iron-sensitive imaging have the potential to track disease progression in PD. However, validation of these progression biomarkers is only beginning, and more work is required for multisite validation, the sample size for use in a clinical trial, and drug-responsiveness of most of these biomarkers. At present, the most clinical trial-ready biomarker is free-water diffusion imaging of the substantia nigra and seems well established to be used in disease-modifying studies in PD. A variety of structural imaging biomarkers are promising candidates to be progression biomarkers in PD. Further studies are needed to elucidate the sensitivity, reliability, sample size, and effect of confounding factors of these progression biomarkers.

Keywords: Biomarkers; Diffusion-weighted MRI; Free-water; Parkinson’s disease; Progression; Structural MRI.

PubMed Disclaimer

References

    1. Parkinson’s Disease Foundation. Statistics on Parkinson’s. http://www.pdforg/en/parkinson_statistics (Accessed July 12, 2018).
    1. Pringsheim T, Jette N, Frolkis A, Steeves TD. The prevalence of Parkinson’s disease: a systematic review and meta-analysis. Mov Disord. 2014;29(13):1583–90. 10.1002/mds.25945. - DOI - PubMed
    1. Kalia LV, Lang AE. Parkinson’s disease. Lancet (London, England). 2015;386(9996):896–912. 10.1016/s0140-6736(14)61393-3. - DOI - PubMed
    1. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci. 1973;20(4):415–55. - PubMed
    1. Cheng HC, Ulane CM, Burke RE. Clinical progression in Parkinson disease and the neurobiology of axons. Ann Neurol. 2010;67(6):715–25. 10.1002/ana.21995. - DOI - PMC - PubMed

Publication types